ALACRIS THERANOSTICS GMBH

Their core work

Alacris Theranostics is a Berlin-based biotech SME specializing in computational disease modeling and predictive medicine. They build virtual patient models and pathway simulation platforms that help predict how individual patients will respond to treatments — particularly in oncology and autoimmune diseases. Their core technical capability lies in integrating multi-omics data (genomics, single-cell data) with agent-based modeling to create digital twins of disease progression. This positions them at the intersection of bioinformatics, precision medicine, and high-performance computing.

What they specialise in

How they've shifted over time

Alacris's early H2020 projects (2015-2016) were more diverse, spanning tissue repair (TREGeneration), coronary artery disease simulation (SMARTool), and even optical protein sequencing (PROSEQO). From 2016 onward, they consolidated around computational disease modeling, culminating in coordinating CanPathPro — their flagship cancer pathway platform. By 2019, their focus had sharpened further toward precision medicine infrastructure: virtual patients, single-cell genomics, disease trajectory prediction, and cloud computing for biomedical simulation.

Alacris is converging on cloud-based virtual patient platforms that integrate multi-omics data, positioning them as a computational precision medicine infrastructure provider.

How they like to work

Alacris primarily operates as a specialized partner within large research consortia (6 of 7 projects as participant), contributing computational modeling expertise to clinical and biomedical teams. With 142 unique partners across 23 countries, they maintain an exceptionally broad network for an SME, suggesting they are a sought-after specialist rather than a repeat-partner loyalist. Their one coordinator role (CanPathPro, €3.4M) demonstrates they can lead large projects when the topic aligns squarely with their core platform.

Alacris has collaborated with 142 unique partners across 23 countries — a remarkably wide network for a small company, indicating strong reputation as a computational biology specialist. Their Berlin base and German institutional connections likely anchor the network, but the geographic spread is pan-European.

What sets them apart

Alacris occupies a rare niche: a private SME with deep expertise in virtual patient modeling and agent-based disease simulation, bridging the gap between academic bioinformatics and clinical decision support. Unlike large pharma companies or university groups, they offer a focused, productizable computational platform — particularly their cancer pathway modeling capability built through CanPathPro. For consortium builders, they bring the computational modeling layer that translates complex omics data into actionable clinical predictions.

Highlights from their portfolio

• CanPathPro
  Their only coordinator role with by far the largest funding (€3.4M) — building a predictive cancer pathway modeling platform that represents their core product vision.
• iPC
  Demonstrates their cloud-based virtual patient capability applied to paediatric oncology, combining HPC, data harmonization, and precision medicine.
• 3TR
  Long-running project (to 2026) tackling treatment non-response across autoimmune diseases using integrative genomics and disease trajectory modeling — shows their expanding scope beyond oncology.